文献速递肝肾功能剂量调整

肾功能不全对双重GIP/GLP-1受体激动剂替尔泊肽药代动力学的影响

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
PubMed 文献 · Clin Pharmacokinet · 2021-03-29

结果显示肾功能不全对替尔泊肽暴露无临床相关影响,各肾功能不全组与正常肾功能组AUC和Cmax的90%CI多数跨越1,仅中度肾功能不全组AUC增加25-29%。结论提示肾功能不全患者可能无需调整剂量。

要点

  • 肾功能不全对替尔泊肽药代动力学无临床相关影响。
  • 仅中度肾功能不全组AUC增加25-29%,其余组与正常肾功能组相似。
  • 肾功能不全患者使用替尔泊肽可能无需调整剂量。

核心结论

  • 肾功能不全对替尔泊肽药代动力学无临床相关影响,肾功能不全患者可能无需调整剂量。

研究设计与样本

  • 所有受试者单次皮下注射替尔泊肽5 mg,测定给药后至648小时的血浆浓度以计算药代动力学参数。

主要发现

  • 各肾功能不全组与正常肾功能组的替尔泊肽暴露相似。
  • 各肾功能不全组与正常肾功能组比较,AUC和Cmax比值的90%CI均跨越1,但中度肾功能不全组AUC增加25-29%。
  • 替尔泊肽暴露与eGFR之间无显著关系。
  • 肾功能不全组和正常肾功能组报告的不良事件较少,多数为轻度,肾功能不全组以胃肠道事件为主。

关键数值与推荐

  • 主要分析评估各肾功能不全组与正常肾功能组AUC和Cmax的比值(90%CI)。
  • 中度肾功能不全组AUC较正常肾功能组增加25-29%。

临床怎么用

  • 临床使用替尔泊肽时,肾功能不全患者可能无需根据肾功能调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The pharmacokinetics (PK) and single-dose tolerability of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist being developed for once-weekly treatment of type 2 diabetes (T2D), weight management, and nonalcoholic steatohepatitis, was evaluated in subjects with renal impairment versus healthy subjects with normal renal function. METHODS: Forty-five subjects, categorized by baseline renal status, i.e. mild (n = 8, estimated glomerular filtration rate [eGFR] 60-89 mL/min/1.73m2), moderate (n = 8, eGFR 30-59 mL/min/1.73m2), severe renal impairment (n = 7, eGFR < 30 mL/min/1.73m2), end-stage renal disease requiring dialysis (n = 8), and normal renal function (n = 14, eGFR ≥ 90 mL/min/1.73m2), received a single subcutaneous dose of tirzepatide 5 mg. Tirzepatide plasma concentrations up to 648 h postdose were measured to compute PK parameters. The primary analysis evaluated the ratios of area under the plasma concentration-time curves (AUCs) and maximum plasma drug concentration (Cmax) of renal impairment versus the normal renal function group (90% confidence interval [CI]). In addition, the relationship between PK parameters and continuous variables of renal function was assessed by linear regression. RESULTS: Tirzepatide exposure was similar across renal impairment groups and healthy subjects. The 90% CI of ratios of AUCs and Cmax comparing each renal impairment group versus normal renal function spanned unity, except for a 25-29% increase in AUCs in the moderate renal impairment group. There was no significant relationship between tirzepatide exposure and eGFR. Few adverse events were reported across the renal impairment and normal renal function groups. The majority were mild in severity and of a gastrointestinal nature in the renal impairment groups. CONCLUSION: There were no clinically relevant effects of renal impairment on tirzepatide PK. Dose adjustment may not be required for patients with renal impairment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03482024.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Urva S, Quinlan T, Landry J, et al. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2021. PMID: 33778934. doi:10.1007/s40262-021-01012-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。